Ipsen at a glance

Innovation for

patient care

Press releases

01 September 2014

Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe

29 August 2014

Ipsen: 2014 half-year results and 2014 objectives

YOU ARE ON IPSEN'S CORPORATE WEBSITE

The corporate website is governed by the International Federation of Pharmaceutical Manufacturers & Associations code of practice.
Certain information provided on this website may not be strictly in conformity with the French regulations on advertising.

> Close